Fate Therapeutics Inc
FATE
NASDAQ
Biotechnology
$2.57
USD
+0.05 (+1.98%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $293.73M
Volume 2.0M
Revenue
$6.49M
TTM
-23.4%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-126.00M
TTM
+26.5%
YoY
Operating Cash Flow
$-101.94M
TTM
+11.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 1.9 | 1.7 | 1.4 | 1.3 | 2.1 |
YoY Growth | -71.8% | -43.4% | -26.4% | -20.3% | +9.2% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 1.9 | 1.7 | 1.4 | 1.3 | 2.1 |
Selling, General & Administrative | 11.4 | 10.6 | 10.7 | 9.6 | 8.8 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 38.9 | 36.5 | 36.1 | 34.3 | 33.2 |
Operating Income | -37.0 | -34.7 | -34.7 | -33.0 | -31.1 |
EBITDA | -33.7 | -31.5 | -31.7 | -30.1 | -28.4 |
Other Income / Expense | -0.0 | -0.1 | 0.1 | -0.1 | -0.6 |
Total Other Income / Expense | 2.9 | 2.5 | 2.3 | 1.8 | 1.0 |
Income Before Income Taxes | -34.1 | -32.3 | -32.4 | -31.2 | -30.2 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -34.1 | -32.3 | -32.4 | -31.2 | -30.2 |
Consolidated Net Income / Loss | -34.1 | -32.3 | -32.4 | -31.2 | -30.2 |
Net Income Attributable to Common Shareholders | -34.1 | -32.3 | -32.4 | -31.2 | -30.2 |
Basic EPS | -$0.29 | -$0.27 | -$0.27 | -$0.26 | -$0.25 |
Diluted EPS | -$0.29 | -$0.27 | -$0.27 | -$0.26 | -$0.25 |
Basic Shares Outstanding | 118.5M | 119.0M | 119.3M | 120.0M | 120.4M |
Diluted Shares Outstanding | 118.5M | 119.0M | 119.3M | 120.0M | 120.4M |